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Abstract
Background—Late-middle age HIV patients are prone to fatigue despite effective viral control 
by antiretroviral therapies. Rodent models to recapitulate this phenotype are still not available.
Hypothesis—Drug treatment may compromise muscle strength and physical performance more 
in older individuals with pre-existing metabolic disorders than normal young ones.
Methods—Kaletra was given to overweight male mice at late-middle age and normal young 
adults; both on a rodent diet containing 30% fat calorie. Body composition and grip strength were 
measured at baseline and after drug treatment. Rota-rod running, insulin and glucose tolerance 
were measured at the end of the experiment. Drug effect on metabolic activity and spontaneous 
movements were assessed using the metabolic cage system. Representative muscle and fat tissue 
were analyzed for protein and mRNA expression. Selected findings were tested using murine 
C2C12 myotubes.
Results—Kaletra reduced grip strength in both young and older mice but impaired rotarod 
performance only in the old. Spontaneous movements were also reduced in Kaletra-treated old 
mice. Kaletra reduced IGF-1 expression in all muscle groups tested for the old and in cultured 
myotubes but to a less extent in the muscle of young animals. Reduced IGF-1 expression 
correlated with increased expression of muscle-specific atrogene MAFbx and MuRF1. Kaletra 
also increased abdominal fat mass markedly in the old animals and to a less extend in the young.
Conclusion—Long-term Kaletra intake aggravated abdominal obesity and impaired muscle 
strength. This effect was worse in older animals than in normal young adults.
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Introduction
Successful antiretroviral therapy significantly increases mortality and increasing attention is 
paid to associated morbidities, such as complaints of weakness and fatigue, which are 
common complaints in patients chronically taking antiretroviral therapy [1–3]. Both viral 
infection and antiretroviral drugs may contribute to this syndrome. Since it is not feasible to 
study long-term drug side-effect on non-infected humans, reproduction of clinical side 
effects in a rodent model can be helpful to facilitate research in this area. Indeed, drug-
related insulin resistance, dyslipidemia, and mitochondrial toxicity have been reported in 
rodents treated with antiretrovirals [4–12]. Limitations for these studies include exclusive 
use of healthy young animals and paucity of functional measurements. Since most HIV 
patients in USA are now ≥ 50 years (www.cdc.gov/hiv), over-weighted, and with fatty diet, 
outcomes of studies on young rodents may not reflect the drug effects experienced by these 
real-life patients. For instance, Kaletra markedly increases plasma lipids in healthy volunteer 
[13], which was recapitulated in young mice [9]. However, HIV patients taking Kaletra 
display only modest increase in plasma lipids [14,15]. In this work, we investigated the 
effect of Kaletra on over-weighted mice at a late-middle age with a high fat diet, conditions 
that are more reflective of the reallife patient conditions. For comparison, a cohort of young 
adult mice was studied in parallel. Kaletra (lopinavir/ritonavir 4:1) was selected for this 
work because of its proven long-term efficacy [16].
Material and Methods
This study aims to determine the effect of Kaletra on functional and metabolic health in 
older mice with pre-existing over-weighted. Selected experiments were conducted in young 
mice for comparison. This research complied with the NIH guidelines on laboratory animal 
care and Institutional Animal Care and Use Committees (IACUC) of Boston University 
approved the protocol. Mice of two age groups were used. The older ones were at 20 month 
and over-weighted (~30% body fat mass at baseline) and the younger ones were at 6 month 
(15% body fat). Both were given a high fat food of 30% fat calorie. Detailed methods on 
diet, drug administration, and serum drug measurement, functional and molecular 
measurements are presented in the supplemental information section.
Results
Effects of kaletra on physical performance and body composition in older mice with pre-
existing overweight
Animals were first assessed by their grip strength before and after seven weeks of Kaletra 
treatment. As shown in Figure 1A (left panel), the control group displayed an increase of 
grip strength after the dietary switch, while Kaletra-treated mice showed a decrease in grip 
strength in the same period, resulting in a significant 14% difference between the two 
groups. The maximal speed that Kaletra-treated mice could reach on a rota-rod was also 
substantially lower than that of the control animals (Figure 1A, right panel). Using the 
metabolic cage system, we found that Kaletra reduced the nocturnal activity (Figure 1B, left 
panel) but not diurnal activity (data not shown). O2 consumption and CO2 production were 
reduced in the Kaletra-treated animals in both nocturnal and diurnal periods (Figure 1B, 
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right panel). Kaletra (data not shown) did not affect respiration exchange rate. Despite these 
changes in physical activity and metabolic rate, we found no gross drug effect on body 
weight and composition measured by in vivo NMR (Figure 1C).
Effect of kaletra on plasma lipids, liver, fat, and muscle mass
As shown in Figure 2A, liver weight was increased in mice treated with Kaletra but liver or 
plasma triglyceride concentrations were similar between the two groups, which were 
somewhat unexpected based on previous rodent studies [8–11], but nevertheless compatible 
with clinical reports that over 90% of the patients taking Kaletra don’t show dramatic 
increase in plasma lipids (< 12%) [14,15]. Kaletra has been shown to strikingly reduce fat 
mass in young mice [9,11]. However, in the old over-weighted mice used for this work, 
Kaleta caused a 40% increase in abdominal epididymal fat, without affecting inguinal fat 
(Figure 2B, upper panel). A decrease in perirenal fat mass was found (Figure s1), similar to 
that reported by others [11]. As shown in Figure 2B (lower panel), despite a decrease in grip 
strength and spontaneous activity, we were not able to detect any difference in muscle 
weight for gastrocnemius and quadriceps, two major weight-bearing muscles with different 
ratio of fast- and slow-twitching fibers, and tibialis anterior (TA) which consists of primarily 
fast-twitching myofibers. No significant difference was found in muscle fiber cross-sectional 
areas either after histological staining (data not shown). These results are in agreement with 
the clinical reports showing no correlation between lean mass and frailty in HIV patients 
taking anti-retrovirals [17].
Effects of kaletra on insulin and glucose tolerance
Kaletra and other protease inhibitors can cause acute but reversible inhibition on insulin-
stimulated glucose uptake [4]. To assess the long-term drug effect on insulin resistance, we 
performed insulin and glucose tolerance tests on the animals. Both control and Kaletra-
treated animals has similar fasting (150–165 mg/dl) and non-fasting (175–180 mg/dl) 
glucose concentrations. Kaletra did not affect glucose tolerance (Figure 2C) nor insulin 
tolerance (Figure 2D). Although the blood glucose trough appeared moderately higher in the 
Kaletra-treated animals (Figure 2D), the calculated AUC (area under curve) between 15–90 
min was not significant different (9190 +/− 278 vs 10510 +/− 546 for control and Kaletra 
groups, respectively, means +/− se, p=0.4, n=6). No difference was detected in serum insulin 
concentration either (0.55 +/− 0.05 vs. 0.49 +/− 0.04 ng/ml for control and Kaletra-treated 
groups, p=0.4, n= 6). These results are also compatible with the relevant clinical 
observations [15,18].
Kaletra does not reduce fat tissue expression of markers for adipogenesis
Lopinavir may inhibit adipocyte differentiation in vitro but the in vivo results are 
inconclusive [19–22,8,9]. As shown in Figure 3A (upper panel), Kaletra did not change 
inguinal fat expression of (Peroxisome proliferator-activated receptor gamma) PPARγ2 and 
Ccaat-enhancer-binding proteins (C/EBPα), both are master transcription factors that 
coordinately regulate adipogenesis [23] or their downstream target adiponectin but reduced 
expression of inflammatory cytokine TNFα, a cytokine known to inhibit adipogenesis [24]. 
In epididymal fat, Kaletra moderately increased expression of PPARγ2 and adiponectin and 
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simultaneously reduced expression of TNFα (Figure 3A, lower panel). Together, these 
results do not suggest Kaletra negatively regulate adipocyte differentiation in vivo. 
Additionally, Kaletra reduced the ratio of cyclin D1 (CCND1) to cyclin D3 (CCND3) in 
both inguinal and epididymal fat (Figure 3B). Since D1 is typically found in proliferating 
cells while D3 is important for fat cell terminal differentiation and maintenance [25–27], a 
reduction in the D1/D3 ratio suggests that Kaletra promote fat cell differentiation in vivo, 
which could contribute to explain the marked increase of epididymal fat mass (Figure 2B). 
Besides, Kaletra-associated reduction in TNFα expression implies that fat tissue 
inflammation is unlikely a main contributor to the drug-induced loss of in vivo physical and 
metabolic function.
Kaletra suppresses muscle expression of local IGF1 (IGF-1Ea), reduces mTOR activity, 
and reciprocally increases expression of muscle-specific atrogenes
Insulin-like growth factor IGF-1Ea is a locally produced autocrine/paracrine that promotes 
muscle repair and regeneration while suppressing catabolism, which also contributes to 
muscle strength [28–30]. As shown in Figure 4A, IGF-1Ea was down regulated by Kaletra 
in all three muscle groups tested, with a reciprocal correlation with expression of MuRF1 
and MAFbx, two of the muscle-specific E3 ubiquitin ligases typically up-regulated in acute 
muscle atrophy [28]. Western analysis shows that Kaletra reduced phosphorylation 
(inactivated form) of Foxo3a and, to a less extent, Foxo1, the downstream target of IGF1 
and also the transcription factors of MuRF1 and MAFbx. As shown in Figure 4B (right 
panel), loss of muscle IGF-1Ea was associated with reduced phosphorylation (activated 
form) of mTOR, the master anabolic regulator, and its downstream target eiF4G, implying 
that long-term treatment with Kaletra negatively regulates protein translation in muscle. 
However, Kaletra equally inhibited not every component in this pathway. For instance, 
Kaletra (Figure 4B) did not reduce phosphorylation (activated form) of eiF4B and S6. The 
discordance may suggest activation of endogenous compensatory mechanism at various 
levels trying to maintain protein translation, which might explain the relatively well-
maintained muscle mass (Figure 2B).
Effect of Kaletra on young adult mice
The results described thus far suggest that long-term Kaletra intake reduces skeletal muscle 
strength in the over-weighted old mice. We also tested whether this effect occurred in drug-
treated young adults. As shown in supplemental Figure s2, young mice displayed a marked 
increase in body weight after diet switching which was primarily attributed to fat mass 
increment. The control also showed a small increase in lean mass which was not observed in 
Kaletra-treated ones (Figure s2, upper right panel). Kaletra did not affect subcutaneous and 
increased epididymal fat only marginally (Figure s2). The drug increased liver weight but 
did not change liver or serum triglyceride concentrations (Figure s2) and had no effect on 
skeletal muscle mass for all three muscle groups examined (Figure s2). The younger mice 
had greater grip strength at baseline than the older ones (1.46 +/− 0.05 N vs. 1.32 +/− 0.03 
N, for the young and the old, respectively, p=0.0001, n=12 for the old and n=20 for the 
young). After drug treatment, grip strength did not change in the control but was reduced in 
the Kaletra-treated group (Figure s3), as was found in the older ones (Figure 1A). However, 
Kaletra did not affect the rota-rod performance in the young (both control and Kaletra-
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treated mice were able to run beyond 35 rpm for > 30 min without falling, which was more 
than twice of the speed achieved by the old control). This result is in agreement with a 
recent report by Pistell et al showing that Kaletra impairs cognitive performance but not 
motor performance in adult mice [11]. Since grip strength positively correlates with 
cognitive function [31–35], Kaletra-induced decline in grip strength could be partially 
related to cognitive impairment reported by Pistell et al. [11].
Consistent with the data on the older animals, Kaletra had no effect on glucose tolerance in 
the young (Figure s4A). Kaletra did not affect insulin-stimulated rapid drop of blood glucose 
but delayed the recovery (Figure s4B) with a smaller area under curve in the insulin 
tolerance test than the control with AUC of 14790 +/− 827 for the control and 12180 +/− 
591 for the Kaletra group (arbitrary unit, p=0.017, n= 10). Consistently, serum insulin 
concentration was lower in Kaletra-treated younger mice (Figure s4C). These results are 
consistent previous studies showing that selected HIV protease inhibitors can reduce serum 
insulin in mice under both low fat and high fat dietary conditions [10], although opposite 
findings have also been reported [11].
As shown in Figure s5, similar to the results from older mice, Kaletra markedly reduced 
IGF-1Ea expression in TA muscle in young mice, associated with increased expression of its 
downstream gene MuRF1 but MAFbx was not affected. Kaletra also reduced expression of 
IGF-1Ea in gastrocnemius muscle although to a less extent and with no significant impact 
on expression of MuRF1 or MAFbx. For quadriceps, Kaletra-related reduction in IGF-1Ea 
expression was marginal but an increase in MuRF1 mRNA was detected, with no effect on 
MAFbx. These results, together with the lack of drug effect on rotarod performance, suggest 
that young mice could be less vulnerable to Kaletra-mediated impairment on skeletal muscle 
strength than the old ones.
Kaletra inhibits IGF1 expression and signaling in culturally differentiated murine myotubes
To test whether Kaletra-induced impairment on skeletal muscle strength could be a result of 
direct interaction between the drug and muscle cells, we studied the effect of lopinavir and 
ritonavir on cultured murine C2C12 myotubes. We were able to recapitulate some but not all 
of the in vivo effects of Kaletra on muscle. Incubation with lopinavir/ritonavir (4:1) for 24 h 
resulted in a dose-dependent reduction in IGF1 expression in differentiated myotubes 
(Figure 4C) and undifferentiated myoblasts (Figure s6). Myogenin, the transcription factor 
that coordinates skeletal muscle development and repair, was dose-dependently inhibited by 
lopinavir/ritonavir, implying that Kaletra had a direct inhibitory effect on myotube 
development. In addition, lopinavir/ritonavir reduced phosphorylation of Foxo3a/Foxo1 as 
well as its upstream AktTh308 when myotubes were incubated in a basal medium without or 
with exogenous IGF-1 at a low concentration (Figure 4D). This effect was reversed by high 
concentration of exogenous IGF1. However, in contrast to the in vivo findings, lopinavir/
ritonavir did not reduce but enhanced basal and IGF1-induced activation of mTOR and its 
downstream eiF4G (Figure 4D). Furthermore, drug-induced loss of IGF1 and activation of 
Foxo3a/Foxo1 in cultured myotubes were not correlated with an increase in expression of 
MuRF1 and MAFbx (Figure 4C). This is probably because both MuRF1 and MAFbx are 
muscle-specific proteasome ligases whose expression is positively correlated with the 
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progression of myotube development. However, even when normalized to the expression 
level of myogenin, lopinavir/ritonavir still did not correlate with MuRF1/MAFbx expression 
(not shown). Together, these results demonstrated that alternative signaling pathways are 
involved in regulation of MuRF1/MAFbx expression under cell culture condition.
Discussion
We reported the first evidence that long-term treatment with Kaletra in old male over-
weighted mice resulted in a decrease in grip strength, rota-rod performance, spontaneous 
activity and metabolic activity. Similar decrease in grip strength was found in Kaletra-
treated young animals but with no effect on rota-rod performance, (metabolic cage was not 
used for the young). No drug effect was detected on muscle mass in both age groups. The 
drug-induced functional impairments could reflect compromised muscle strength and 
cognitive decline [36]. Our findings are in line with the clinical observations that suggest a 
disconnection between steady muscle mass and compromised muscle strength in HIV 
patients taking antiretroviral therapies [37–40].
In association with a loss of gross physical performance, we reported the first evidence that 
Kaletra reduced local IGF1 expression in skeletal muscle. This effect was found to be more 
consistent in the old mice among three muscle groups with different myofiber composition 
and weight-bearing capacity, whereas the results in the young mice were less conclusive. 
The finding was recapitulated in cultured myotubes and myoblasts, implying a result of 
direct interaction between the drug and muscle cells. The drug-induced loss of IGF 1 was in 
turn associated with reduced suppression of Foxo1/3a both in vivo and in vitro. Kaletra was 
associated with a loss in activation of mTOR/eiF4G and increased expression of muscle-
specific atrogenes MuRF1 and MAFbx. Similarly correlated reciprocal change between 
IGF1 and MuRF1/MAFbx has been reported in skeletal muscle atrophy of different causes 
[28]. The drug-induced loss of IGF1 could be responsible for the loss of suppression on 
Foxo1/3a [41,42], which in turn increases transcription of MuRF1/MAFbx [43–45]. It has 
been shown that infusion of indinavir increases muscle expression of MuRF1 without 
changing systemic IGF1 concentration but the drug effect on local IGF1 was not analyzed 
[46]. Of note, although widely used as a marker for muscle atrophy, the actual role of 
MuRF1/MAFbx remains a subject of debate [47]. Hence, they may serve as molecular 
markers for drug-mediated change in skeletal muscle but not necessarily the cause for the 
functional decline in these animals.
Another important finding from this work is that Kaletra increased abdominal fat in old mice 
that were already overweight but less so in young mice. This is in line with the commonly 
documented abdominal obesity in older HIV patients taking antiretroviral drugs [17]. Our 
data, to our knowledge, documented the first such observation in a rodent model as previous 
studies exclusively show that antiretroviral drugs reduce body weight in rodents [9,11,48]. 
The discrepancy may be related to age and body composition of the animals at the baseline 
and suggests that older animals with pre-existing overweight may be a better model for this 
type of studies. Additionally, the approaches of drug delivery may contribute to the different 
outcomes between the current and previous studies (see supplemental information). 
Consistent with the increase of fat mass, our data suggest that long-term treatment with 
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Kaletra do not inhibit adipocyte differentiation at least in epididymal fat depot, as evidenced 
by increased expression of PPARgamma2 and adiponectin, decreased expression of cytokine 
TNFalpha and decreased ratio of CCND1/CCND3. Although in contrast with previous in 
vitro studies [19,49,50], the discrepancy is not unexpected considering the high drug doses 
commonly used in cell culture studies.
In summary, our data demonstrated that long-term treatment with Kaletra caused marked 
impairment of muscle strength measured as grip strength, rota-rod performance, and 
nocturnal spontaneous movements and metabolic activity in old weighted mice. The drug 
caused a similar impairment of grip strength in young adult animals but not in rota-rod 
running. IGF1 expression was reduced in all muscle groups examined for the old mice and 
in some but not as conclusive for the young. Reduced IGF1 expression was associated with 
an increase in expression of muscle atrogenes. The drug-induced inhibition on IGF1 
expression was recapitulated in cultured myotubes. Our data demonstrated that Kaletra 
impaired muscle strength at both a functional level and a molecular level, causing more 
damage in the old over-weighted animals than in the young. These drug side effects 
occurred without gross loss of muscle mass. Based on the well-established role of IGF1 in 
muscle development and maintenance, as well as its proven capacity to reverse muscle 
atrophy in a variety of patho-physiological conditions [51,52], it will be interesting to 
investigate if the Kaletra-induced functional decline can be offset by pharmaceutical 
manipulation of muscle IGF1 signaling.
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Figure 1. Long-term treatment with Kaletra impairs physical strength and reduces spontaneous 
physical and metabolic activity without gross change of body composition
A. Grip strength (Left panel) measurement by an automatic force transducer (Columbus 
Instruments, Columbus, OH). Max speed (right panel) of physical performance measured by 
Rota Rod (Columbus Instruments, Columbus, OH). B. Activity (Left panel), oxygen (O2) 
consumption (upper right), and carbon dioxide (CO2) production were measured by 
Oxymax system (Columbus Instruments, Columbus, OH). C. Body composition determined 
by nuclear magnetic resonance (NMR; EchoMRI-100, Echo Medical System, Houston, TX).
Kaletra was provided to C57BL/6 mice beginning at age 20 month when the mice were 
moderately overweight. The drug was mixed with food (0.1 % wt/wt) for form pellets using 
a commercial service. The same diet without drug was given to the control animals. (A, left 
panel) Grip strength was measured at baseline and in week 7 after drug treatment. (A, right 
panel) Maxium speed of rota-rod running achieved by the animals in week 7. (B, upper 
panel) Spontaneous movements, O2 consumption, and CO2 production rate recorded in the 
metabolic cages between 7 pm and 12 am (darker period 7 pm – 7 am), measured in week 7. 
Xtot and Xamb: total movements and ambulatory movements, both recorded as the number 
of beam breaking along the X-direction. (B, lower panel) Mean values of parameters 
measured above during nocturnal and diurnal periods. (C) Body mass at baseline and in 
week 7, measured by in vivo NMR. Results are shown as means +/− se, N = 6 for each 
group. Between-group comparison was analyzed by Student’s t test.
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Figure 2. Effects of Kaletra on body composition, plasma and hepatic lipids, insulin and glucose 
tolerance
(A) Liver weight, liver triglyceride concentration and plasma triglyceride concentration. (B). 
Tissue weight for major fat depots and hind limb muscle groups, expressed as percentage of 
body weight. (C) Glucose tolerance test. (D) Insulin tolerance test. Results are shown as 
means +/− se, N = 6 for each group. Between-group comparison was analyzed by Student‘s t 
test.
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Figure 3. Effects of Kaletra on fat tissue mRNA expression
(A) Expression of adipocyte transcription factor PPARγ2 and C/EBPα, adiponectin, and 
TNFalpha in abdominal epididymal (upper panel) and subcutaneous inguinal (lower panel) 
fat depots. (B) The ratio of mRNA expression between cyclin D1 and cyclin D3 (CCND1/
CCND3). All results are normalized to house-keeping gene HPRT, shown as means +/− se. 
N = 6, Student’s t test.
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Figure 4. Effects of Kaletra on muscle IGF1-related molecular changes in skeletal muscle and 
cultured myotubes
(A) Messenger RNA expression of IGF-1Ea and related muscle atrogenes in tibialis anterior 
(TA), quadriceps (Quad) and gastrocnemius (Gastro) muscle groups. Expression of each 
gene was first normalized to house-keeping gene HPRT and presented as a fraction of the 
control. (B, left panel) Western analysis of phosphor-Foxo3aser318/321, phosphor-
Foxo1ser256, and total Foxo3a in quadriceps muscle, with GAPDH as loading control. (B, 
right panel) Western analysis for phosphor-mTORser2448, phosphor-eiF4Gser1108, phosphor-
eiF4Bser422, and phosphor-S6ser235/236 in quadriceps, with GAPDH as loading control. 
Results are representative of N = 6 for each group with three of each group for display. (C) 
Expression of IGF1, myogenin (MyoG), MAFbx and MuRF1 in cultured C2C12 myotubes 
exposed to different concentration of lopinavir (lopinavir:ritonavir = 4:1). The experiment 
was repeated twice in duplicates. Results were normalized to house-keeping gene HPRT and 
shown as means+/− se, a > b > c, p < 0.05, analyzed by One-way ANOVA with post hoc 
Tukey’s test. (D) Western analysis of C2C12 myotubes treated with low and high dose of 
IGF1 for the phosphorylation of relevant downstream targets. Myotubes were pre-incubated 
with lopinavir/ritonavir (4:1) at 3 ug/ml of lopinavir in 2% horse serum for 24 h. Cells were 
then washed with serum-free medium and incubated with serum-free medium added the 
same concentration of lopinavir/ritonavir for two hours. IGF1 was then added and cells were 
harvested after 30 mins. Results are representative of three independent experiments.
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